Vytorin does not appear to be unsafe – American Heart Association
Schering-Plough Corp and Merck & Co are defending their shared cholesterol treatments, Vytorin and Zetia, in advertisements in The New York Times after a failed study generated negative publicity. – Merck/Schering-Plough Pharmaceuticals released results from the ENHANCE trial, which found that the ezetimibe/simvastatin (Zetia/Zocor) combination drug known as Vytorin was no more effective in reducing artery plaque build-up than simvastatin (Zocor) alone. There were no statistically significant differences in the safety of the drugs, which are used to lower cholesterol.